<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Elective oophorectomy or ovarian conservation at the time of hysterectomy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Elective oophorectomy or ovarian conservation at the time of hysterectomy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Elective oophorectomy or ovarian conservation at the time of hysterectomy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan D Reed, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard T Sharp, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21231548"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hysterectomy can be performed with or without the removal of the ovaries and/or fallopian tubes. Historically, it had been common practice to counsel patients in their mid-40s or older who were planning hysterectomy for benign indications to undergo concomitant bilateral salpingo-oophorectomy (BSO). The rationale for oophorectomy in these patients was to reduce the risks of ovarian cancer and reoperation for ovarian pathology, and the short interval to spontaneous menopause. This approach also assumed nearly universal treatment with postmenopausal hormone therapy. </p><p>However, with a growing understanding of the potential long-term health consequences of elective oophorectomy, and the potential advantages of elective salpingectomy alone (without oophorectomy), the pendulum has swung toward ovarian conservation, particularly in premenopausal patients [<a href="#rid1">1</a>]. Randomized trials comparing elective oophorectomy and ovarian conservation are lacking, therefore clinicians rely on data from cohort studies for patient counseling. </p><p>The management of the ovaries at the time of hysterectomy for benign disease will be reviewed here. Opportunistic salpingectomy, techniques for salpingectomy and oophorectomy, management of patients with gynecologic malignancy or those with a hereditary ovarian cancer syndrome, and general principles of menopause are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause"</a>.)</p><p></p><p class="headingAnchor" id="H12797502"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective oophorectomy</strong> – Removal of the ovaries in a patient who has no known medical indication for this procedure (eg, ovarian pathology, hereditary ovarian cancer syndrome). <strong>Elective salpingo-oophorectomy </strong>(removal of the ovaries and fallopian tubes) may also be performed in such patients. </p><p></p><p class="bulletIndent1">While the term "elective" is widely used in the literature, other terms, such as "opportunistic," "concurrent," or "incidental" may also be used. In this topic, we retain the term "elective" in most instances to emphasize shared decision-making and patient choice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opportunistic salpingectomy</strong> – Removal of the fallopian tubes in a patient with a general population risk of ovarian cancer syndrome. Risk reduction occurs because many malignancies currently categorized as ovarian cancers may arise in the tubal epithelium. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk-reducing salpingo-oophorectomy</strong> – Removal of the ovaries and fallopian tubes in a patient with a hereditary ovarian cancer syndrome. (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent1">Risk-reducing salpingectomy with delayed oophorectomy has also been described in selected patients. (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer", section on 'BSO versus salpingectomy alone'</a>.)</p><p></p><p>The term <strong>prophylactic salpingo-oophorectomy</strong> has been used inconsistently in the literature and will not be used in this topic, except when it was the term used in a particular study. It has been used variously to refer to salpingo-oophorectomy for the prevention of ovarian cancer in either patients at an average risk or those with a hereditary ovarian cancer syndrome [<a href="#rid2">2,3</a>]. </p><p class="headingAnchor" id="H1285625663"><span class="h1">HOW TO CHOOSE</span><span class="headingEndMark"> — </span>The approach to oophorectomy at time of hysterectomy for benign indications must be individualized and includes comprehensive counseling regarding risks and benefits and shared decision-making between the clinician and patient.</p><p class="headingAnchor" id="H1444651437"><span class="h2">Pelvic pathology</span><span class="headingEndMark"> — </span>Patients undergoing hysterectomy for benign indications should be evaluated for extrauterine pelvic pathology (eg, with physical examination and/or pelvic imaging). Indications for concurrent oophorectomy may include: </p><p class="bulletIndent1"><span class="glyph">●</span>Benign ovarian neoplasms – Benign ovarian neoplasms (eg, mature cystic teratoma, serous cystadenoma, mucinous cystadenoma) and management with oophorectomy versus ovarian cystectomy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis", section on 'Benign neoplasms'</a> and  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Oophorectomy versus cystectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometriosis – The risk of reoperation for endometriosis-related concerns appears to be lower if the ovaries are removed at the time of hysterectomy [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Surgical treatment options'</a>.)</p><p></p><p class="bulletIndent1">In a retrospective study of nearly 4500 patients undergoing hysterectomy for endometriosis, patients with ovarian conservation compared with oophorectomy were more likely to undergo at least one reoperation (13 versus 5.3 percent) during the 10-year (median) follow-up period [<a href="#rid5">5</a>]. Oophorectomy and adhesiolysis were the most common reoperation procedures. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubo-ovarian abscess – In patients requiring surgical management of tubo-ovarian abscess, the risk of reoperation is higher if one or both ovaries are conserved [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/16419.html" rel="external">"Management and complications of tubo-ovarian abscess", section on 'Drainage and surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic adhesions/pelvic pain – Preoperative pelvic adhesions and/or pelvic pain are risk factors for residual ovary syndrome (ROS), which is characterized by pelvic pain in a patient in whom an ovary was intentionally left in place during hysterectomy. In one study, the incidence of ROS was reported to be between 0.9 to 3.4 percent [<a href="#rid7">7</a>]. However, the majority of such patients underwent open abdominal hysterectomy, and these data may not be transferable to patients today, who are more likely to undergo a laparoscopic procedure. </p><p></p><p class="bulletIndent1">While hysterectomy with bilateral salpingo-oophorectomy (BSO) is a common approach for such patients, patients should be counseled that if hysterectomy is performed alone, subsequent oophorectomy can frequently be accomplished with a laparoscopic approach [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">ROS differs from ovarian remnant syndrome (ORS) which is defined as the presence of ovarian tissue in a patient who has had previous oophorectomy. (See  <a class="medical medical_review" href="/z/d/html/17176.html" rel="external">"Ovarian remnant syndrome"</a>.)</p><p></p><p>Oophorectomy in these contexts is <strong>not</strong> elective. However, even in these circumstances, patients should be counseled preoperatively about the risk-to-benefit balance of bilateral oophorectomy versus ovarian conservation.</p><p class="headingAnchor" id="H499013773"><span class="h2">Menopausal status</span><span class="headingEndMark"> — </span>The choice of oophorectomy or ovarian conservation at the time of hysterectomy also depends on the patient's age and menopausal status. </p><p class="bulletIndent1"><span class="glyph">●</span>For most <strong>premenopausal</strong> patients who undergo hysterectomy for benign indications, we suggest ovarian conservation. While bilateral oophorectomy provides a small absolute cancer risk reduction for patients at an average risk of ovarian or breast cancer, it is associated with long-term health consequences. (See <a class="local">'Benefits of elective oophorectomy'</a> below and <a class="local">'Long-term health risks'</a> below.) </p><p></p><p class="bulletIndent1">However, elective oophorectomy may be reasonable for patients who place a higher priority on ovarian cancer prevention than on other long-term health risks, particularly those who are age 51 years old or older [<a href="#rid9">9,10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <strong>menopausal</strong> patients, elective bilateral oophorectomy may be health neutral. In a decision analysis based on a comprehensive review of observational data, the risks and benefits of elective oophorectomy compared with ovarian conservation at time of hysterectomy approximated each other after age 65 years [<a href="#rid11">11</a>]. Ovarian conservation until age 65 years benefited long-term survival. However, in a revised analysis of these data, those who had hysterectomy with or without oophorectomy at ≥50 years had similar survival to age 80 years [<a href="#rid10">10</a>]. The results of these models may not be applicable to all patients as the study cohorts included mostly White patients and salpingectomy status was unknown. (See <a class="local">'All-cause mortality'</a> below.)</p><p></p><p class="headingAnchor" id="H4066738647"><span class="h2">Ovarian cancer risk factors</span><span class="headingEndMark"> — </span>All patients should be assessed for risk factors for ovarian and breast cancer. This is especially important when pelvic surgery is planned  (<a class="graphic graphic_table graphicRef59585" href="/z/d/graphic/59585.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef65717" href="/z/d/graphic/65717.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors"</a>.)</p><p>Patients for whom a familial cancer syndrome is suspected should be offered genetic counseling and testing  (<a class="graphic graphic_table graphicRef65717" href="/z/d/graphic/65717.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef59832" href="/z/d/graphic/59832.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p>For patients with some risk factors, but who do not have, or have not been tested for, a hereditary cancer syndrome, the decision regarding oophorectomy is more nuanced. Counseling must be individualized and include a detailed discussion of the advantages and disadvantages of elective oophorectomy, opportunistic salpingectomy, and elective salpingo-oophorectomy. </p><p class="headingAnchor" id="H24792980"><span class="h1">BENEFITS OF ELECTIVE OOPHORECTOMY</span></p><p class="headingAnchor" id="H24793011"><span class="h2">Ovarian cancer risk reduction</span><span class="headingEndMark"> — </span>Bilateral oophorectomy reduces, but does not eliminate, the risk of developing ovarian cancer. Removal of the fallopian tubes provides additional risk reduction and there is an abundance of data demonstrating that the fallopian tubes, rather than the ovaries, are the primary site of most epithelial, fallopian tube, and peritoneal carcinomas (EOC). EOC discovered incidentally at the time of bilateral salpingo-oophorectomy (BSO) has also been described. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a> and  <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Incidental finding'</a>.)</p><p>The degree of ovarian cancer risk reduction from BSO at the time of hysterectomy in the general population has been illustrated in the following studies: </p><p class="bulletIndent1"><span class="glyph">●</span>The Nurses' Health study (NHS) was a prospective cohort study including approximately 30,000 participants who had a hysterectomy for benign disease with or without ovarian conservation [<a href="#rid12">12,13</a>]. The average age at time of surgery was 43 to 47 years and the average age at enrollment was 51 years; the majority (94 percent) of subjects were White. Subjects were followed for up to 28 years, allowing adequate time to assess outcomes that are more common for patients over age 60 years, including cardiovascular disease (CVD) and stroke, chronic kidney disease, dementia, osteoporosis, breast cancer, ovarian cancer, and all-cause mortality (see <a class="local">'Long-term health risks'</a> below). Given the small gap between surgery and enrollment, and the long follow-up duration, we regard the NHS as having some of the best available data on this subject. </p><p></p><p class="bulletIndent1">During the 28 years of follow-up, patients who underwent hysterectomy with bilateral oophorectomy compared with hysterectomy alone had fewer ovarian cancer-related deaths (4 versus 44 patients; hazard ratio [HR] 0.06, 95% CI 0.02-0.17) [<a href="#rid13">13</a>]. The analyses were adjusted for family history of ovarian cancer and duration of oral contraceptive use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Women's Health Initiative (WHI) Observational Study was a prospective study that included 25,448 females who had a hysterectomy for benign disease; 56 percent of study participants had concomitant BSO [<a href="#rid14">14</a>]. Individuals in this study were initially invited to participate in the WHI randomized trial that evaluated postmenopausal hormone therapy but were either found ineligible or declined to participate in the trial. The average age at time of hysterectomy was 49 years or younger, and the average age at enrollment was 63 years; 82 percent of the subjects were White. Subjects were followed for only eight years. </p><p></p><p class="bulletIndent1">During the 7.6 years (average) of follow-up, patients in the BSO group compared with the ovarian conservation group had fewer cases of incident ovarian cancer (2 versus 33 per 10,000 females) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Limitations of the WHI Observational Study include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Short duration of follow-up (8 years compared with 28 years in the NHS). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A long gap between surgery and enrollment (average 14 years). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential for recall bias, which likely affects risk estimates. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who had outcomes of interest (CVD and stroke, dementia, osteoporosis, breast cancer, ovarian cancer, and all-cause mortality) that occurred during the interval from hysterectomy to enrollment were not included, introducing a significant survivor bias. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The study also reported that BSO did not have significant adverse effects on all-cause mortality, coronary heart disease, hip fracture, or cancer, but the study had insufficient statistical power to detect such differences.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent cohort study including over 195,000 patients undergoing hysterectomy between 1996 and 2010 in Canada, 24 percent of patients underwent concomitant BSO [<a href="#rid15">15</a>]. The cumulative 20-year incidence rate of ovarian cancer was lower among patients in the BSO group compared with the ovarian (and tubal) conservation group (0.08 versus 0.46 percent; absolute risk difference [ARD] 0.38 percent, 95% CI 0.32-0.45). In a subgroup analysis including patients ≥50 years, the ARD was slightly higher (0.62 percent, 95% CI 0.47-0.77). This study did not include patients who underwent bilateral salpingectomy with ovarian preservation at the time of hysterectomy in the analysis.</p><p></p><p>By contrast, unilateral oophorectomy has not been proven to reduce the risk of ovarian cancer. In a multicenter case-control study between 1992 and 1999 and including 1031 patients with ovarian cancer, rates of prior unilateral oophorectomy or unilateral oophorectomy plus hysterectomy were similar between groups [<a href="#rid16">16</a>]. However, in another case-control study including 129 patients with ovarian cancer, patients with a history of unilateral oophorectomy compared with controls had a decreased rate of ovarian cancer (2.9 versus 13.6 percent, odds ratio [OR] 0.2; 95% CI 0.04-0.7) over the 16-year study period [<a href="#rid17">17</a>]. Further study of this issue is needed.</p><p class="headingAnchor" id="H8214361"><span class="h2">Breast cancer risk reduction</span><span class="headingEndMark"> — </span>Bilateral oophorectomy reduces the risk of breast cancer, although the age at which this benefit occurs is uncertain [<a href="#rid18">18,19</a>]. The reduced risk of breast cancer is likely due to reduced exposure to reproductive hormones (ie, estrogen and progesterone) from the premenopausal ovaries; taking hormone therapy following bilateral oophorectomy does not affect the risk reduction associated with oophorectomy [<a href="#rid18">18</a>]. This effect is also seen in patients at high risk of breast cancer. (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer", section on 'Candidates'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In the NHS, oophorectomy was associated with a reduction in breast cancer incidence only in patients who underwent the procedure at age 47.5 years or younger [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in the WHI Observational Study, a reduction in breast cancer risk only occurred in patients who underwent oophorectomy at age &lt;40 years and did not take estrogen therapy [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including over 49,000 patients at average risk for breast cancer who underwent hysterectomy for benign disease and were followed for a median of 4.5 years, those who had concomitant BSO compared with those who underwent hysterectomy alone had a lower risk of developing breast cancer (HR 0.86, 95% CI 0.75-0.98) after controlling for age, race, income, and comorbidities [<a href="#rid20">20</a>]. Rates of incident breast cancer were lower for patients with BSO in every age group except those ≥60 years. </p><p></p><p>The effect of menopausal hormone therapy (MHT) on breast cancer risk is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Breast cancer'</a>.)</p><p class="headingAnchor" id="H557450170"><span class="h2">Effects on other cancers</span><span class="headingEndMark"> — </span>The effect of oophorectomy on the development of other cancers is less clear. </p><p>In the WHI Observational Study, patients undergoing oophorectomy compared with ovarian conservation had similar rates of lung and colorectal cancers [<a href="#rid14">14</a>]. By contrast, in the NHS study, patients undergoing oophorectomy had higher rates of lung cancer (HR 1.26, 95% CI 1.02-1.56) but similar rates of colorectal cancers [<a href="#rid12">12</a>]. In a subsequent cohort study evaluating the risk of cancer and premenopausal oophorectomy, those undergoing oophorectomy (1562 patients) compared with age-matched referent controls had a similar risk of lung and colorectal cancers during the 18-year (median) follow-up period [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H24793003"><span class="h2">Avoiding the need for subsequent oophorectomy</span><span class="headingEndMark"> — </span>Reoperation for ovarian pathology occurs in 3 to 9 percent of patients who retain one or both ovaries after hysterectomy [<a href="#rid7">7,22,23</a>]. However, for most patients undergoing hysterectomy, the possible need for subsequent surgery does <strong>not</strong> appear to justify the deleterious long-term consequences of oophorectomy. (See <a class="local">'Consequences of elective oophorectomy'</a> below.)</p><p>The Mayo Clinic Cohort Study of Oophorectomy and Aging (MOA) is the largest study to report the risk of subsequent oophorectomy following hysterectomy [<a href="#rid23">23</a>]. In this retrospective study of approximately 10,000 subjects, patients with versus without a history of hysterectomy had a higher rate of oophorectomy at 30 years of follow-up (9.2 versus 7.3 percent, HR 1.2, 95% CI 1-1.4). The cumulative incidence of subsequent oophorectomy at 30 years for patients with one preserved ovary or with both ovaries intact was 4 and 10.6 percent, respectively. Other studies that reported lower risk of reoperation had short follow-up, were not population based, and lacked a control group [<a href="#rid7">7,22</a>].</p><p>Some data suggest that the reoperation rate is higher in patients who undergo abdominal or laparoscopic hysterectomy compared with vaginal hysterectomy [<a href="#rid24">24</a>]. The reason for such a difference is uncertain, but it may be that vaginal hysterectomy is typically not performed when ovarian pathology is suspected.</p><p>For patients in whom subsequent oophorectomy is required, a laparoscopic rather than an open abdominal technique can often be performed. In one study including 35 patients with pelvic pain after hysterectomy with ovarian conservation, almost all patients (91 percent) were able to have a successful laparoscopic oophorectomy [<a href="#rid8">8</a>]. However, surgical adhesions from prior hysterectomy may make a laparoscopic approach difficult. In a retrospective study including 744 patients undergoing laparoscopic adnexal surgery at an academic tertiary care center, those with prior hysterectomy compared with no hysterectomy had higher rates of intraoperative (3.2 versus 0.8 percent; risk ratio [RR] 4, 95% CI 1.1–14.7) and postoperative complications (15.3 versus 9.4 percent; RR 1.6, 95% CI 1–2.6) [<a href="#rid25">25</a>]. Patients with prior hysterectomy also had a fivefold increase in rates of conversion to laparotomy. </p><p class="headingAnchor" id="H24792988"><span class="h1">CONSEQUENCES OF ELECTIVE OOPHORECTOMY</span></p><p class="headingAnchor" id="H2436631825"><span class="h2">Surgical menopause</span><span class="headingEndMark"> — </span>Surgical menopause (caused by bilateral oophorectomy, or the removal of the remaining ovary in a patient who has previously undergone unilateral oophorectomy) results in an abrupt drop in circulating estrogen levels, abrupt rise in follicle-stimulating hormone (FSH) levels, and complete cessation of ovarian estrogen, androgen, and progesterone production [<a href="#rid26">26-28</a>]. Patients typically experience bothersome menopausal symptoms (eg, hot flashes, sleep disturbance, mood changes). When not contraindicated, these symptoms may be treated with menopausal hormone therapy; significant risks of such therapy have <strong>not</strong> been demonstrated in patients who were premenopausal at the time of oophorectomy, and withholding estrogen therapy from such patients may pose significant risks. (See <a class="local">'Role of estrogen therapy after hysterectomy with oophorectomy'</a> below and <a class="local">'Long-term health risks'</a> below and  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p>This contrasts with natural menopause, which is typically characterized by a gradual waxing and waning of estradiol and FSH production, in association with unpredictable ovulatory and anovulatory cycles, that occurs over an interval of up to 10 years (though the variability in hormone levels is most dramatic over a period of four years) [<a href="#rid29">29,30</a>]. Intact postmenopausal ovaries continue to produce androgens including testosterone, androstenedione, and dehydroepiandrosterone (DHEA), and very small amounts of estradiol and <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">estrone</a> for many years [<a href="#rid31">31</a>]. Although estrogen secretion by the postmenopausal ovary eventually ceases, ovarian secretion of small amounts of testosterone and DHEA may continue into the eighth decade of life [<a href="#rid27">27,31</a>]. </p><p>Nonovarian sources of sex steroids include the adrenal glands and widespread target tissues, including fat, where aromatization of androgens into estrogen occurs. The extent to which nonovarian sex steroid hormone synthesis differs between patients who have experienced surgical compared with natural menopause has been debated [<a href="#rid27">27,28</a>], but it appears that total androgen levels remain lower after surgical than natural menopause [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H24792996"><span class="h2">Surgical morbidity</span><span class="headingEndMark"> — </span>Operative complications are uncommon in patients undergoing elective oophorectomy at the time of hysterectomy. However, the risk of such complications is increased if adhesions or other intraabdominal pathology are present. </p><p>Risk of complications may also depend on surgical route; however, data are conflicting. For hysterectomies performed via laparotomy or laparoscopy, concomitant oophorectomy does not appreciably increase the complexity of the procedure. By contrast, when oophorectomy is combined with vaginal hysterectomy, the procedure is potentially more difficult. The degree of difficulty depends on adnexal anatomy (ie, high versus low in the pelvis), mobility, and the experience of the surgeon. Representative studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of over two million patients in the United States who underwent hysterectomy for benign indications from 1998 to 2006 and identified via the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, those undergoing vaginal hysterectomy (15 percent of patients) with versus without bilateral salpingo-oophorectomy (BSO) experienced an increase in complications (odds ratio [OR] 1.12, 95% CI 1.08-1.17) [<a href="#rid32">32</a>]. By contrast, patients undergoing abdominal (72 percent) and laparoscopic (13 percent) hysterectomy with versus without BSO had decreased rates of complications (OR 0.91, 95% CI 0.89-0.94 and OR 0.89, 95% CI 0.83-0.94, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of over nine million patients who underwent hysterectomy between 1979 and 2004 and identified via the United States National Hospital Discharge Survey database, those undergoing hysterectomy with versus without BSO had higher rates of complications (organ injury: adjusted OR 1.4, 95% CI 1-1.8; gastrointestinal complication: adjusted OR 1.8, 95% CI 1.3-2.4) [<a href="#rid33">33</a>]. The majority (84 percent) of the procedures were open abdominal hysterectomies, which no longer reflects current practice patterns. Furthermore, the authors pooled complications from laparoscopic and vaginal procedures for the remaining 16 percent of patients. </p><p></p><p>Because available data do not consider the indication for oophorectomy (eg, pelvic adhesions, large pelvic mass), the potential effect of adnexal pathology on surgical morbidity is unknown. Therefore, further study regarding the impact of oophorectomy on surgical morbidity at the time of benign hysterectomy is needed.</p><p>Surgical risk of opportunistic salpingectomy, as well as the procedures for adnexal removal or conservation, are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction", section on 'Perioperative outcomes'</a> and  <a class="medical medical_review" href="/z/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route", section on 'Adnexal conservation or removal'</a> and  <a class="medical medical_review" href="/z/d/html/3286.html" rel="external">"Hysterectomy: Laparoscopic", section on 'Adnexa'</a> and  <a class="medical medical_review" href="/z/d/html/3308.html" rel="external">"Hysterectomy: Vaginal", section on 'Adnexal evaluation and surgery'</a>.)</p><p class="headingAnchor" id="H21231420"><span class="h2">Long-term health risks</span><span class="headingEndMark"> — </span>Accumulating evidence indicates that surgical removal of the ovaries may be associated with serious long-term health consequences [<a href="#rid12">12-14,34-42</a>]. Such risks may also be greater for patients who are younger at the time of oophorectomy and those not taking estrogen therapy [<a href="#rid35">35-38,41,42</a>].</p><p>The highest quality data regarding long-term health outcomes of elective oophorectomy compared with ovarian conservation at time of hysterectomy are from prospective and retrospective studies. No randomized trials have investigated this issue [<a href="#rid43">43</a>]. Potential long-term health effects are discussed in the following sections. </p><p class="headingAnchor" id="H325404"><span class="h3">All-cause mortality</span><span class="headingEndMark"> — </span>Bilateral oophorectomy at younger age appears to be associated with increased all-cause mortality [<a href="#rid13">13,19,20,34,35,44-46</a>], especially among patients who do not take estrogen therapy. While the mechanism of this effect is unknown, evidence is suggestive that hypoestrogenism may be an important factor leading to endothelial dysfunction.</p><p>The association of BSO at the time of hysterectomy with an increase in all-cause mortality has been illustrated in the following studies: </p><p class="bulletIndent1"><span class="glyph">●</span>In the Nurses' Health Study (NHS), patients who underwent bilateral oophorectomy compared with ovarian conservation had higher all-cause mortality (16.8 versus 13.3 percent, hazard ratio [HR] 1.13, 95% CI 1.06-1.21) over 28 years of follow-up [<a href="#rid13">13</a>]. Among patients &lt;50 years, the increased mortality risk associated with oophorectomy was seen primarily in patients who never used estrogen therapy, whereas there was little to no impact on mortality in patients who had ever used, or were currently using, estrogen therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United Kingdom study, a retrospective study of a United Kingdom national database including 113,679 patients ages 35 to 45 years old who underwent hysterectomy for benign conditions from 2004 to 2014, conservation of at least one ovary was associated with a lower all-cause mortality (0.6 versus 1 percent; HR 0.64, 95% CI 0.55-0.73) [<a href="#rid34">34</a>]. While the finding was statistically significant, the absolute difference was quite small (0.4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Australian Longitudinal Study on Women's Health including over 3300 females with a history of hysterectomy prior to age 50 years, the mortality rate was higher for those who underwent concomitant oophorectomy compared with hysterectomy alone (40 versus 32 deaths per 10,000 person-years) [<a href="#rid44">44</a>]. The between-group difference in mortality was highest among patients not receiving hormone therapy (74 versus 30 deaths per 10,000 person-years), whereas there was no between-group difference among patients taking hormone therapy (35 deaths per 10,000 in each group).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Mayo Clinic Cohort Study of Oophorectomy and Aging (MOA) was a retrospective population-based cohort study of 2365 patients in Olmstead County, Minnesota who underwent unilateral or bilateral oophorectomy for benign disease; almost all the patients were White [<a href="#rid35">35,45</a>]. For some analyses, patients from the cohort were compared with controls who had not had an oophorectomy and were identified via random digit telephone dialing [<a href="#rid46">46</a>]. The median age at time of surgery was 44 years among premenopausal patients who had a bilateral oophorectomy and 62 years among postmenopausal patients. Patients who had a bilateral oophorectomy were followed for an average of 25 years; 95 percent had the oophorectomy at the time of hysterectomy. Although this study was retrospective, it includes prospective data from centralized medical records regarding the surgical, pharmacy, and outcome data for all participants. Thus, recall bias was limited and there was access to long-term follow-up data. This was also the only study to analyze elective and indicated oophorectomies separately. </p><p></p><p class="bulletIndent1">In this study, an increase in all-cause mortality compared with referent patients without oophorectomy was found only in those patients in whom the oophorectomy was<strong> </strong>indicated due to a benign tumor or inflammation; the causes of death were not reported [<a href="#rid35">35,45</a>]. Among patients &lt;45 years, mortality during the 25 years of follow-up was higher for patients who underwent prophylactic oophorectomy compared with those who did not have an oophorectomy (27 versus 16 percent; HR 1.67, 95% CI 1.16-2.4). The increased mortality risk associated with oophorectomy was seen primarily in patients who did not receive estrogen therapy. The study lacked sufficient statistical power to detect a difference in outcome in other patients who underwent prophylactic oophorectomy. Further study of the distinction between indicated and elective oophorectomies is needed. (See <a class="local">'Pelvic pathology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including over 49,000 patients at average risk for breast cancer who underwent hysterectomy for benign disease and were followed for a median of 4.5 years, all-cause mortality was higher for patients who underwent BSO compared with hysterectomy alone (3.1 versus 1.2 percent); this association persisted across all age groups [<a href="#rid20">20</a>]. </p><p></p><p>By contrast, in the Women's Health Initiative (WHI) Observational Study, patients who underwent hysterectomy with bilateral oophorectomy compared with ovarian conservation had <strong>no</strong> increase in mortality for any age group subset [<a href="#rid14">14</a>]. A discussion of this study’s limitations can be found above. (See <a class="local">'Ovarian cancer risk reduction'</a> above.)</p><p class="headingAnchor" id="H21231434"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Bilateral oophorectomy at a younger age and early (40 to 45 years) or premature (&lt;40 years) menopause appear to be associated with an increased risk of cardiovascular disease (CVD), including coronary heart disease and stroke [<a href="#rid13">13,19,34,41,47-52</a>]. Estrogen therapy, however, may mitigate these adverse effects in such patients [<a href="#rid12">12,38,48,50</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early/premature menopause</strong> – The associations between CVD, oophorectomy, and early/premature menopause were illustrated in the following studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a pooled analysis of 10 observational studies including over 203,7000 postmenopausal patients, surgical compared with natural menopause was associated with higher risk of CVD (2.7 versus 1.8 CVD events per 1000 person-years; HR 1.22, 95% CI 1.16–1.28) [<a href="#rid53">53</a>]. However, the association diminished after adjusting for age at menopause (adjusted HR [aHR] 1.05, 95% CI 1.03-1.06). Lower age at menopause was associated with an increased incident of CVD in both groups, but use of hormone therapy mitigated this risk. (See <a class="local">'Role of estrogen therapy after hysterectomy with oophorectomy'</a> below.)</p><p></p><p class="bulletIndent2">Similarly, surgical menopause at age &lt;35 years compared with natural menopause occurring at age 50 to 54 years was associated with increased risk of stroke (2 versus 0.6 events per 1000 person-years; aHR 2.6, 95% CI 2-3.3); the risk was somewhat less with surgical menopause occurring at ages 35 to 39 years (1.3 versus 0.6 events per 1000 person-years; aHR 1.9, 95% CI 1.6-2.3), and 40 to 44 years (1 versus 0.6 events per 1000 person-years; aHR 1.5, 95% CI 1.3-1.8) [<a href="#rid53">53</a>]. While other studies have not reported this association [<a href="#rid52">52,54</a>], they were limited by the inability to ascertain use of hormone therapy or small numbers of subjects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Earlier studies reported that CVD risk with earlier menopause was limited to current smokers [<a href="#rid55">55</a>], while a 2005 study reported the effect in patients who never smoked [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">"Overview of atherosclerotic cardiovascular risk factors in females", section on 'Early menopause'</a>.)</p><p></p><p class="bulletIndent1">By contrast, in the WHI Observational Study, patients with hysterectomy plus BSO compared with ovarian conservation, at any age, had similar rates of CVD [<a href="#rid14">14</a>]. However, the lack of increased risk for CVD with BSO could be explained by the following: Nearly 80 percent of patients were &gt;40 years at the time of BSO, 66 percent were current users of estrogen therapy, and over 60 percent had used estrogen therapy for &gt;5 years. Other limitations of this study are detailed above. (See <a class="local">'Ovarian cancer risk reduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menopausal transition</strong> – There may not be an increased risk for CVD among patients who undergo BSO in the menopause transition. </p><p></p><p class="bulletIndent1">In the Study of Women's Health Across the Nation, a prospective cohort study including over 3000 premenopausal patients (ages 42 to 52 years) not using hormone therapy and followed annually for up to 11 years, those undergoing hysterectomy with (5.4 percent) versus without (3.9 percent) BSO had similar changes in CVD risks factors including lipids, insulin resistance, blood pressure, hemostatic, and inflammatory factors [<a href="#rid57">57</a>]. Similarly, in the United Kingdom cohort study discussed above, patients with oophorectomy in the menopause transition compared with those who experienced natural menopause had similar CVD outcomes [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H3050475240"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>Oophorectomy prior to age 50 appears to be associated with an increased risk of chronic kidney disease (CKD), and the relationship between early menopause and CKD appears to be bidirectional. The mechanism that confers this relationship, however, is unclear. It is hypothesized that the potential increased risk for CKD associated with young age at bilateral oophorectomy is due to endothelial dysfunction, glomerulosclerosis, and increased glomerular permeability.</p><p>In the Mayo Clinic Cohort Study of Oophorectomy and Aging (MOA-2), patients who underwent oophorectomy prior to age 50 years compared with those who did not had a higher risk of CKD (aHR 1.42, 95% CI 1.14-1.77); the risk was highest in patients ≤45 years (aHR 1.59, 95% CI 1.15-2.19) [<a href="#rid58">58</a>]. Hormone replacement therapy seemed to mitigate some of this risk; in patients ≤45 years, the aHR was lower in those who took hormone replacement therapy (HR 1.52) compared with those who did not (HR 2.07). </p><p>Similarly, in a subsequent report from the database of the National Health and Nutrition Examination Survey, patients experiencing surgical menopause at age &lt;45 compared with ≥45 years were more likely to have CKD (OR 1.38, 95%CI 1.1-1.8) [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H21231441"><span class="h3">Cognitive function and neurologic disease</span><span class="headingEndMark"> — </span>Oophorectomy prior to menopause is associated with an increased risk of cognitive impairment or dementia, as well as parkinsonism [<a href="#rid36">36,42,60-65</a>]. Estrogen therapy may be neuroprotective in these patients. (See  <a class="medical medical_review" href="/z/d/html/7422.html" rel="external">"Estrogen and cognitive function", section on 'Timing of exposure'</a> and  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Cognitive function and dementia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive impairment or dementia</strong> – In the Mayo Clinic Cohort Study discussed above (see <a class="local">'All-cause mortality'</a> above), among patients who underwent bilateral oophorectomy before menopause compared with those who did not undergo oophorectomy, an increased risk of cognitive impairment or dementia was restricted to those who were &lt;48 years old at time of surgery and who did not take estrogen therapy from time of surgery through age 50 years (HR 1.89, 95% CI 1.27-2.83) [<a href="#rid42">42,60,61</a>]. Patients &lt;46 years with bilateral oophorectomy compared with no oophorectomy also had increased odds of mild cognitive impairment (adjusted odds ratio [aOR] 2.2, 95% CI 1.4-3.5) and poorer performance on cognitive tests approximately 30 years later [<a href="#rid66">66</a>]. Increased rates of dementia were also found in patients with prior oophorectomy in a large Danish cohort study [<a href="#rid67">67</a>], but this did not reach statistical significance.</p><p></p><p class="bulletIndent1">Small observational studies have shown a decrease in specific cognitive functions after bilateral oophorectomy, including verbal fluency, verbal memory, procedural learning, and some other executive functions [<a href="#rid36">36,62</a>]. Neurocognitive performance was worse when oophorectomy occurred at younger ages and worse with a greater decline in estradiol levels, but it was better when hormone therapy was initiated after oophorectomy. The extent to which observed improvements in neurocognitive performance with estrogen therapy might be attributable to improvements in sleep and relief of hot flashes versus direct effects on the brain has been debated [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parkinsonism</strong> <strong>and Parkinson disease</strong> – In the Mayo Clinic Cohort Study, patients who underwent bilateral oophorectomy before the onset of menopause had an increased risk of parkinsonism compared with no oophorectomy (2.6 versus 1.2 percent), and the risk increased with younger age at oophorectomy [<a href="#rid61">61,63</a>]. An increase in the risk of Parkinson disease was also found, but this did not reach statistical significance. </p><p></p><p class="bulletIndent1">In a subsequent cohort study including almost 5500 patients (median age 45 years), patients with versus without a history of oophorectomy also had higher rates of examination or medical record-confirmed parkinsonism (HR 1.59; 95% CI 1.02-2.46) [<a href="#rid64">64</a>]. While rates of Parkinson disease were similar between groups overall, rates were higher in those with oophorectomy prior to age 43 years (HR 5, 95% CI 1.1-22.7). </p><p></p><p class="bulletIndent1">A case-control study including 385 females also reported an association with bilateral oophorectomy and Parkinson disease [<a href="#rid68">68</a>]. </p><p></p><p class="headingAnchor" id="H21231462"><span class="h3">Depression and anxiety</span><span class="headingEndMark"> — </span>Some data suggest that bilateral oophorectomy at the time of hysterectomy is associated with a long-term increased risk of developing depression or anxiety [<a href="#rid36">36,42,69</a>] but data are conflicting [<a href="#rid70">70</a>].</p><p>In the Mayo Clinic Cohort Study discussed above, patients who had bilateral oophorectomy compared with those who did not had an increase in onset of symptoms of depression (as diagnosed by a physician, 11 versus 7 percent) or anxiety (7 versus 3 percent) [<a href="#rid36">36</a>]. Median time from oophorectomy to the onset of symptoms of depression or anxiety was approximately 14 years, but differences in rates of occurrence of anxiety and depression were observed within three years following hysterectomy and persisted throughout more than 30 years of follow-up. </p><p>However, data are conflicting. In a subsequent retrospective study including data from 1970 patients in the Study of Women's Health Across the Nation, patients undergoing hysterectomy with (5.2 percent) and without (3.9 percent) oophorectomy experienced a decrease in depressive and anxiety symptoms after surgery; the trajectory was similar among groups [<a href="#rid70">70</a>]. Data from shorter-term studies have also been inconsistent regarding the effect of bilateral oophorectomy on psychological well-being [<a href="#rid71">71,72</a>].</p><p class="headingAnchor" id="H59912207"><span class="h3">Glaucoma</span><span class="headingEndMark"> — </span>Estrogen appears to have neuroprotective effects on the optic nerve and decrease the risk of glaucoma, the second leading cause of blindness world-wide [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/6909.html" rel="external">"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis"</a>.)</p><p>In the Mayo Clinic Cohort Study discussed above, patients with bilateral oophorectomy &lt;43 years compared with referent controls had an increased risk of open-angle-glaucoma (as identified by diagnostic codes and confirmed in a subset chart validation study; aHR 1.6, 95% CI 1.2-2.2) [<a href="#rid39">39</a>]. While this risk was not ameliorated in patients who took estrogen in this study, the numbers were small. </p><p>Similarly, in the NHS (see <a class="local">'Ovarian cancer risk reduction'</a> above), patients who underwent menopause at ≥54 years compared with &lt;54 years had a 50 percent lower risk of developing glaucoma [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H3045939659"><span class="h3">Osteoporosis</span><span class="headingEndMark"> — </span>Menopause is a known risk factor for osteoporosis. </p><p>In the Mayo Clinic Cohort Study, compared with expected rates, patients who were postmenopausal at the time of oophorectomy had an increase in the risk of any osteoporotic fracture (moderate trauma fractures of the hip, spine, or distal forearm; standardized incidence ratio [SIR] 1.54, 95% CI 1.29-1.82) and fractures at other sites (SIR 1.35, 95% CI 1.13-1.59) [<a href="#rid74">74</a>]. Similarly, patients who were premenopausal at the time of surgery had an increased risk of distal forearm (SIR 1.4, 95% CI 1-2) and vertebral fractures (SIR 1.9, 95% CI 1.3-2.8), but not hip fracture [<a href="#rid46">46</a>]. </p><p>By contrast, oophorectomy at the time of hysterectomy was not found to be associated with hip fracture in either the NHS or the WHI Observational Study [<a href="#rid12">12,14</a>]. It is important to note the age of participants in these studies was overall lower than the peak age at which most osteoporotic fractures occur. (See <a class="local">'Ovarian cancer risk reduction'</a> above.)</p><p class="headingAnchor" id="H326764"><span class="h3">Sexual dysfunction</span><span class="headingEndMark"> — </span>Bilateral oophorectomy may result in sexual dysfunction, including changes in libido, arousal, orgasm, satisfaction with sex, and overall sexual outcome, particularly in patients &lt;50 years of age or those experiencing surgical rather than natural menopause [<a href="#rid69">69,75-78</a>]. </p><p>The association of bilateral oophorectomy with sexual dysfunction has been illustrated in the following studies: </p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study evaluating sexual health after treatment for heavy menstrual bleeding and including 5702 patients (mean age 39 to 45 years) undergoing hysterectomy, patients with versus without BSO experienced more loss of libido (severe: OR 1.7 versus 1.3; extreme: OR 1.8 versus 1.4) and difficult sexual arousal (severe: OR 1.8 versus 1.3; extreme: OR 1.8 versus 1.4) during the five-year study period [<a href="#rid77">77</a>]. Patients treated with endometrial ablation served as the control group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective study evaluating sexual health in 1101 patients undergoing hysterectomy (the majority of whom were &lt;50 years of age), patients undergoing BSO compared with ovarian conservation reported a 2.7-fold higher rate of not experiencing orgasm during the two-year follow-up period [<a href="#rid76">76</a>]. Rates of vaginal dryness were similar between groups; however, the majority (88 percent) of patients undergoing concomitant oophorectomy were taking hormone therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional survey including approximately 2400 females in Europe with no known increased risk of cancer, those who underwent bilateral oophorectomy compared with patients who were premenopausal or had gone through natural menopause were twice as likely to have hypoactive sexual desire symptoms (OR 2, 95% CI 1.4-3.4) [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study including over 30,000 females in the United States, surgical, but not natural, menopause was associated with orgasm difficulties, and more patients with surgical compared with natural menopause experienced decreased in arousal [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/5424.html" rel="external">"Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation", section on 'Age and menopause'</a>.)</p><p></p><p>However, data are conflicting; other studies have found that overall sexual function is unaltered after oophorectomy, or that alterations were explained by preoperative sexual function, indications for surgery, severity of symptoms, and personality traits, rather than by the oophorectomy itself [<a href="#rid78">78,81-84</a>]. However, the majority of patients in these studies were in the menopause transition or were postmenopausal, and many were using hormone therapy. </p><p class="headingAnchor" id="H3942695056"><span class="h1">TRENDS IN ELECTIVE OOPHORECTOMY</span><span class="headingEndMark"> — </span>Given the association of elective oophorectomy with long-term adverse health consequences (see <a class="local">'Long-term health risks'</a> above), utilization of elective oophorectomy at time of hysterectomy is decreasing [<a href="#rid1">1,85,86</a>]. By contrast, opportunistic salpingectomy is not associated with such risks, and rates of salpingectomy are increasing. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction", section on 'Utilization'</a>.)</p><p>In a 2005 United States nationwide study, unilateral or bilateral oophorectomy performed at the time of abdominal, laparoscopic, and vaginal hysterectomy occurred in 68, 60, and 26 percent of patients, respectively; the mean age of patients was between 44 and 49 years [<a href="#rid87">87</a>]. In a subsequent study including over 190,000 hysterectomies for benign indication between 2005 and 2011 in California, concomitant oophorectomy was performed in 30 percent of patients [<a href="#rid86">86</a>]. While rates of oophorectomy decreased over time (2005: 12,227 patients; 2011: 5930 patients), the percentage of oophorectomies with no reason for removal disproportionately remained stable (38 percent), with significant racial disparities appreciated.</p><p>Data from the Mayo Clinic Cohort Study of Oophorectomy and Aging (MOA) also confirm decreasing rates of bilateral oophorectomy at time of hysterectomy; from 2000 to 2018 rates decreased from 18 to 2.5 percent [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H804435678"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H828715123"><span class="h2">Role of estrogen therapy after hysterectomy with oophorectomy</span><span class="headingEndMark"> — </span>Patients with premature (&lt;40 years) or early (40 to 45 years) menopause due to bilateral oophorectomy are different from those who reach natural menopause (median age of 51 years), and data regarding the use of hormone therapy in naturally menopausal patients should not be extrapolated to those with surgical menopause [<a href="#rid88">88-91</a>].</p><p>In our practice, for patients with surgical menopause, we prescribe either transdermal estradiol (100 mcg daily) or an estradiol vaginal ring (100 mcg daily), which is roughly equivalent to 2 mg daily of oral micronized estradiol and based on the average daily production of estradiol by the premenopausal ovary. These doses are higher than those recommended for postmenopausal patients and are similar to the doses recommended for patients with premature ovarian insufficiency. A progestogen for endometrial protection is not needed. While androgen therapy may be used for selected patients with sexual dysfunction, the routine use of androgen therapy in this population is not well established, and long-term safety data are lacking [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Surgical menopause'</a> and  <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Routine use of testosterone therapy'</a>.)</p><p>Data from the Women's Health Initiative (WHI) randomized trials are informative, and use of <a class="drug drug_general" data-topicid="9424" href="/z/d/drug information/9424.html" rel="external">conjugated equine estrogen</a> (CEE) alone is not associated with the risks seen in users of CEE plus progestin therapy [<a href="#rid93">93</a>]. In the WHI Estrogen-Alone Trial, patients ages 50 to 79 with prior hysterectomy were assigned to CEE or placebo for a median of 7.2 years [<a href="#rid94">94</a>]. While the overall benefits and risks of CEE were similar for patients with and without bilateral salpingo-oophorectomy (BSO), the risk of all-cause mortality was lower for those between the ages of 50 and 59 who had BSO and were treated with CEE (hazard ratio [HR] 0.68, 95% CI 0.48-0.96). All-cause mortality was similar in other age groups. This differential effect based on patient age at the initiation of hormone use is referred to as the "timing effect" and highlights the need for individualized care when discussing initiation of hormone therapy with patients who have had elective oophorectomy. Observational data also consistently indicate that some of the long-term health consequences of bilateral oophorectomy can be ameliorated with estrogen therapy until at least 60 years of age [<a href="#rid13">13,35,38,42,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Estimates of risk in women 50 to 59 years'</a> and  <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Timing of exposure'</a>.) </p><p>Discussions of hormone therapy types, initiation, and duration of use are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a>.)</p><p class="headingAnchor" id="H3902066696"><span class="h2">Surgical alternatives to oophorectomy for ovarian cancer risk reduction</span><span class="headingEndMark"> — </span>For patients at average risk for ovarian cancer, other surgical procedures (ie, complete salpingectomy, tubal ligation, hysterectomy alone) provide an alternative to oophorectomy for ovarian cancer risk reduction without inducing surgical menopause.</p><p>Procedures that interrupt or remove the fallopian tubes have consistently been shown to reduce the risk of ovarian cancer [<a href="#rid95">95-103</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p>Hysterectomy alone also reduces the risk of developing ovarian cancer. In a meta-analysis of 12 case-control studies, hysterectomy alone was associated with a 34 percent reduction in the risk of ovarian cancer [<a href="#rid104">104,105</a>]. </p><p>While hysterectomy alone does not result in surgical menopause, it does appear to alter ovarian function, even if the ovaries are conserved. This effect is incompletely understood but may be due to impairment of the ovarian blood supply [<a href="#rid106">106-108</a>]. Observational studies have found that patients who undergo hysterectomy develop menopausal symptoms and changes in hormone profiles earlier than patients who do not undergo hysterectomy. In a prospective cohort study including over 500 premenopausal patients, those who had a hysterectomy (both ovaries retained) compared with those who did not have a hysterectomy reached menopause earlier (3.7 years, 95% CI 1.5–6 years); menopause was defined as a single FSH measurement of ≥40 international units/L [<a href="#rid108">108</a>]. Furthermore, among all patients who underwent hysterectomy, those who had one ovary conserved compared with both ovaries conserved reached menopause 4.4 years earlier (95% CI 0.6-7.9 years). </p><p>The role of salpingectomy on ovarian blood supply and hormonal function is discussed separately. </p><p class="headingAnchor" id="H1523909820"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122885.html" rel="external">"Society guideline links: Gynecologic surgery"</a>.)</p><p class="headingAnchor" id="H21231476"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Elective oophorectomy refers to the removal of the ovaries in a patient who has no known indication for this procedure (eg, ovarian pathology, hereditary ovarian cancer syndrome). Other terms (eg, opportunistic, concurrent, incidental) may also be used. By contrast, risk-reducing salpingo-oophorectomy refers to the removal of the tubes and ovaries in a patient at high risk of ovarian or breast cancer due to a known gene mutation; these patients are discussed separately. (See <a class="local">'Terminology'</a> above and  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilateral oophorectomy reduces, but does not eliminate, the risk of developing ovarian cancer. Removal of the fallopian tubes provides additional risk reduction and there is an abundance of data demonstrating that the fallopian tubes, rather than the ovaries, are the primary site of most epithelial, fallopian tube, and peritoneal carcinomas (EOC). (See <a class="local">'Ovarian cancer risk reduction'</a> above and  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bilateral oophorectomy reduces the risk of breast cancer, although the age at which this benefit occurs is uncertain. While some data suggest that the risk reduction occurs only in patients with oophorectomy at &lt;47.5 years, other data suggest that risk reduction may extend to age 60 years. (See <a class="local">'Breast cancer risk reduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term health risks</strong> – Oophorectomy is associated with an increase in the following; estrogen therapy may mitigate some of these risks (see <a class="local">'Long-term health risks'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All-cause mortality</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular disease and stroke</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease</p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive function and neurologic disease</p><p class="bulletIndent2"><span class="glyph">•</span>Depression and anxiety</p><p class="bulletIndent2"><span class="glyph">•</span>Glaucoma</p><p class="bulletIndent2"><span class="glyph">•</span>Osteoporosis</p><p class="bulletIndent2"><span class="glyph">•</span>Sexual dysfunction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How to choose</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most <strong>premenopausal</strong> patients who undergo hysterectomy for benign indications, we suggest ovarian conservation rather than elective oophorectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While bilateral oophorectomy provides a small absolute cancer risk reduction for patients at an average risk of ovarian or breast cancer, it is associated with long-term health consequences. Patients with other pelvic pathology (eg, endometriosis, pelvic pain) may reasonably choose oophorectomy. (See <a class="local">'Menopausal status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <strong>menopausal</strong> patients, elective bilateral oophorectomy may be health neutral. Oophorectomy is reasonable for patients who are 51 years of age or older who place a high priority on ovarian or breast cancer prevention. (See <a class="local">'Menopausal status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oophorectomy may also be performed in patients with risk factors for ovarian cancer, but who do not have, or have not been tested for, a hereditary cancer syndrome. The decision regarding oophorectomy in such patients is more difficult and counseling should include a full discussion of the advantages and disadvantages of elective oophorectomy. (See <a class="local">'Ovarian cancer risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of estrogen therapy</strong> – For premenopausal patients undergoing hysterectomy with concomitant oophorectomy resulting in surgical menopause, we suggest estrogen therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose required for these patients is higher than that used for patients &gt;50 years; we prescribe either transdermal estradiol (100 mcg daily) or an estradiol vaginal ring (100 mcg daily) and typically continue therapy until at least age 60 years. (See <a class="local">'Role of estrogen therapy after hysterectomy with oophorectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives to oophorectomy</strong> – For patients at average risk for ovarian cancer, other surgical procedures (ie, complete salpingectomy, tubal ligation, hysterectomy alone) provide an alternative to oophorectomy for ovarian cancer risk reduction without inducing surgical menopause. (See <a class="local">'Surgical alternatives to oophorectomy for ovarian cancer risk reduction'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Erickson Z, Rocca WA, Smith CY, et al. Time Trends in Unilateral and Bilateral Oophorectomy in a Geographically Defined American Population. Obstet Gynecol 2022; 139:724.</a></li><li><a class="nounderline abstract_t">Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol 2010; 116:733.</a></li><li><a class="nounderline abstract_t">Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011; 121:163.</a></li><li><a class="nounderline abstract_t">Catenacci M, Sastry S, Falcone T. Laparoscopic surgery for endometriosis. Clin Obstet Gynecol 2009; 52:351.</a></li><li><a class="nounderline abstract_t">Long AJ, Kaur P, Lukey A, et al. Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status. Am J Obstet Gynecol 2023; 228:57.e1.</a></li><li><a class="nounderline abstract_t">Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin Obstet Gynecol 1993; 36:433.</a></li><li><a class="nounderline abstract_t">Dekel A, Efrat Z, Orvieto R, et al. The residual ovary syndrome: a 20-year experience. Eur J Obstet Gynecol Reprod Biol 1996; 68:159.</a></li><li><a class="nounderline abstract_t">Salim R, Gray G, Chappatte OA. The feasibility and efficacy of laparoscopic oophorectomy in the management of pelvic pain after hysterectomy. J Obstet Gynaecol 2007; 27:718.</a></li><li><a class="nounderline abstract_t">Faubion SS, Files JA, Rocca WA. Elective Oophorectomy: Primum Non Nocere. J Womens Health (Larchmt) 2016; 25:200.</a></li><li><a class="nounderline abstract_t">Rush SK, Ma X, Newton MA, Rose SL. A Revised Markov Model Evaluating Oophorectomy at the Time of Hysterectomy for Benign Indication: Age 65 Years Revisited. Obstet Gynecol 2022; 139:735.</a></li><li><a class="nounderline abstract_t">Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106:219.</a></li><li><a class="nounderline abstract_t">Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009; 113:1027.</a></li><li><a class="nounderline abstract_t">Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013; 121:709.</a></li><li><a class="nounderline abstract_t">Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 2011; 171:760.</a></li><li><a class="nounderline abstract_t">Cusimano MC, Ferguson SE, Moineddin R, et al. Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy. Am J Obstet Gynecol 2022; 226:220.e1.</a></li><li><a class="nounderline abstract_t">Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005; 97:318.</a></li><li><a class="nounderline abstract_t">Beard CM, Hartmann LC, Atkinson EJ, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000; 10:14.</a></li><li><a class="nounderline abstract_t">Xu Z, Chung HF, Dobson AJ, et al. Menopause, hysterectomy, menopausal hormone therapy and cause-specific mortality: cohort study of UK Biobank participants. Hum Reprod 2022; 37:2175.</a></li><li><a class="nounderline abstract_t">Gottschau M, Rosthøj S, Settnes A, et al. Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy : A Nationwide Cohort Study. Ann Intern Med 2023; 176:596.</a></li><li><a class="nounderline abstract_t">Chow S, Raine-Bennett T, Samant ND, et al. Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications. Am J Obstet Gynecol 2020; 223:900.e1.</a></li><li><a class="nounderline abstract_t">Huo N, Smith CY, Gazzuola Rocca L, et al. Risk of de novo cancer after premenopausal bilateral oophorectomy. Am J Obstet Gynecol 2022; 226:539.e1.</a></li><li><a class="nounderline abstract_t">Plöckinger B, Kölbl H. Development of ovarian pathology after hysterectomy without oophorectomy. J Am Coll Surg 1994; 178:581.</a></li><li><a class="nounderline abstract_t">Casiano ER, Trabuco EC, Bharucha AE, et al. Risk of oophorectomy after hysterectomy. Obstet Gynecol 2013; 121:1069.</a></li><li><a class="nounderline abstract_t">Holub Z, Jandourek M, Jabor A, et al. Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study. Clin Exp Obstet Gynecol 2000; 27:109.</a></li><li><a class="nounderline abstract_t">Alammari RA, Jorgensen EM, Modest AM, et al. Impact of prior hysterectomy on surgical outcomes for laparoscopic adnexal surgery. Surg Endosc 2020; 34:2980.</a></li><li><a class="nounderline abstract_t">Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007; 14:562.</a></li><li><a class="nounderline abstract_t">Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011; 18:30.</a></li><li><a class="nounderline abstract_t">Lasley BL, Crawford SL, Laughlin GA, et al. Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition. Menopause 2011; 18:494.</a></li><li><a class="nounderline abstract_t">Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008; 15:603.</a></li><li><a class="nounderline abstract_t">Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96:746.</a></li><li><a class="nounderline abstract_t">Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92:3040.</a></li><li><a class="nounderline abstract_t">Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010; 116:1088.</a></li><li><a class="nounderline abstract_t">Lowder JL, Oliphant SS, Ghetti C, et al. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol 2010; 202:538.e1.</a></li><li><a class="nounderline abstract_t">Mytton J, Evison F, Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ 2017; 356:j372.</a></li><li><a class="nounderline abstract_t">Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7:821.</a></li><li><a class="nounderline abstract_t">Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008; 14:111.</a></li><li><a class="nounderline abstract_t">Shuster LT, Grossardt BR, Gostout BS, Rocca WA. Prophylactic bilateral oophorectomy jeopardizes long-term health. Menopausal Medicine 2010; 18:S1.</a></li><li><a class="nounderline abstract_t">Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15.</a></li><li><a class="nounderline abstract_t">Vajaranant TS, Grossardt BR, Maki PM, et al. Risk of glaucoma after early bilateral oophorectomy. Menopause 2014; 21:391.</a></li><li><a class="nounderline abstract_t">Pasquale LR, Kang JH. Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study. Eye (Lond) 2011; 25:633.</a></li><li><a class="nounderline abstract_t">Løkkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006; 53:226.</a></li><li><a class="nounderline abstract_t">Rocca WA, Gazzuola Rocca L, Smith CY, et al. Bilateral Oophorectomy and Accelerated Aging: Cause or Effect? J Gerontol A Biol Sci Med Sci 2017; 72:1213.</a></li><li><a class="nounderline abstract_t">Orozco LJ, Tristan M, Vreugdenhil MM, Salazar A. Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women. Cochrane Database Syst Rev 2014; 2014:CD005638.</a></li><li><a class="nounderline abstract_t">Wilson LF, Pandeya N, Byles J, Mishra GD. Hysterectomy status and all-cause mortality in a 21-year Australian population-based cohort study. Am J Obstet Gynecol 2019; 220:83.e1.</a></li><li><a class="nounderline abstract_t">Rocca WA, Gazzuola Rocca L, Smith CY, et al. Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open 2017; 7:e018861.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Crowson CS, Malkasian GD, O'Fallon WM. Fracture risk following bilateral oophorectomy. J Clin Epidemiol 1996; 49:1111.</a></li><li><a class="nounderline abstract_t">Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13:265.</a></li><li><a class="nounderline abstract_t">Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019; 322:2411.</a></li><li><a class="nounderline abstract_t">Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 2011; 32:745.</a></li><li><a class="nounderline abstract_t">Muka T, Oliver-Williams C, Kunutsor S, et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol 2016; 1:767.</a></li><li><a class="nounderline abstract_t">Poorthuis MHF, Yao P, Chen Y, et al. Risks of Stroke and Heart Disease Following Hysterectomy and Oophorectomy in Chinese Premenopausal Women. Stroke 2022; 53:3064.</a></li><li><a class="nounderline abstract_t">Lai JC, Chou YJ, Huang N, et al. The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study. Maturitas 2018; 114:27.</a></li><li><a class="nounderline abstract_t">Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35:1933.</a></li><li><a class="nounderline abstract_t">Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23:178.</a></li><li><a class="nounderline abstract_t">Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061.</a></li><li><a class="nounderline abstract_t">Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.</a></li><li><a class="nounderline abstract_t">Matthews KA, Gibson CJ, El Khoudary SR, Thurston RC. Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women's Health Across the Nation. J Am Coll Cardiol 2013; 62:191.</a></li><li><a class="nounderline abstract_t">Kattah AG, Smith CY, Gazzuola Rocca L, et al. CKD in Patients with Bilateral Oophorectomy. Clin J Am Soc Nephrol 2018; 13:1649.</a></li><li><a class="nounderline abstract_t">Qian D, Wang ZF, Cheng YC, et al. Early Menopause May Associate With a Higher Risk of CKD and All-Cause Mortality in Postmenopausal Women: An Analysis of NHANES, 1999-2014. Front Med (Lausanne) 2022; 9:823835.</a></li><li><a class="nounderline abstract_t">Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69:1074.</a></li><li><a class="nounderline abstract_t">Rocca WA, Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008; 5:257.</a></li><li><a class="nounderline abstract_t">Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 2010; 66:56.</a></li><li><a class="nounderline abstract_t">Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70:200.</a></li><li><a class="nounderline abstract_t">Rocca WA, Smith CY, Gazzuola Rocca L, et al. Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease. JAMA Netw Open 2022; 5:e2238663.</a></li><li><a class="nounderline abstract_t">Crawford SL. Contributions of oophorectomy and other gynecologic surgeries to cognitive decline and dementia. Menopause 2022; 29:499.</a></li><li><a class="nounderline abstract_t">Rocca WA, Lohse CM, Smith CY, et al. Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment. JAMA Netw Open 2021; 4:e2131448.</a></li><li><a class="nounderline abstract_t">Uldbjerg CS, Wilson LF, Koch T, et al. Oophorectomy and rate of dementia: a prospective cohort study. Menopause 2022; 29:514.</a></li><li><a class="nounderline abstract_t">Canonico M, Pesce G, Bonaventure A, et al. Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy. Mov Disord 2021; 36:1696.</a></li><li><a class="nounderline abstract_t">Shoupe D, Parker WH, Broder MS, et al. Elective oophorectomy for benign gynecological disorders. Menopause 2007; 14:580.</a></li><li><a class="nounderline abstract_t">Gibson CJ, Joffe H, Bromberger JT, et al. Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among women in midlife. Obstet Gynecol 2012; 119:935.</a></li><li><a class="nounderline abstract_t">Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993; 14:283.</a></li><li><a class="nounderline abstract_t">Aziz A, Bergquist C, Nordholm L, et al. Prophylactic oophorectomy at elective hysterectomy. Effects on psychological well-being at 1-year follow-up and its correlations to sexuality. Maturitas 2005; 51:349.</a></li><li><a class="nounderline abstract_t">Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study. J Glaucoma 2007; 16:598.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003; 18:900.</a></li><li><a class="nounderline abstract_t">Evans EC, Matteson KA, Orejuela FJ, et al. Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. Obstet Gynecol 2016; 128:476.</a></li><li><a class="nounderline abstract_t">Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999; 282:1934.</a></li><li><a class="nounderline abstract_t">McPherson K, Herbert A, Judge A, et al. Psychosexual health 5 years after hysterectomy: population-based comparison with endometrial ablation for dysfunctional uterine bleeding. Health Expect 2005; 8:234.</a></li><li><a class="nounderline abstract_t">Teplin V, Vittinghoff E, Lin F, et al. Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. Obstet Gynecol 2007; 109:347.</a></li><li><a class="nounderline abstract_t">Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006; 3:212.</a></li><li><a class="nounderline abstract_t">Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970.</a></li><li><a class="nounderline abstract_t">Aziz A, Brännström M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005; 83:1021.</a></li><li><a class="nounderline abstract_t">Aziz A, Bergquist C, Brännström M, et al. Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy. Acta Obstet Gynecol Scand 2005; 84:854.</a></li><li><a class="nounderline abstract_t">Shifren JL, Avis NE. Surgical menopause: effects on psychological well-being and sexuality. Menopause 2007; 14:586.</a></li><li><a class="nounderline abstract_t">Rodríguez MC, Chedraui P, Schwager G, et al. Assessment of sexuality after hysterectomy using the Female Sexual Function Index. J Obstet Gynaecol 2012; 32:180.</a></li><li><a class="nounderline abstract_t">Jacoby VL. Hysterectomy controversies: ovarian and cervical preservation. Clin Obstet Gynecol 2014; 57:95.</a></li><li><a class="nounderline abstract_t">Mahal AS, Rhoads KF, Elliott CS, Sokol ER. Inappropriate oophorectomy at time of benign premenopausal hysterectomy. Menopause 2017; 24:947.</a></li><li><a class="nounderline abstract_t">Jacoby VL, Autry A, Jacobson G, et al. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet Gynecol 2009; 114:1041.</a></li><li><a class="nounderline abstract_t">Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:3975.</a></li><li><a class="nounderline abstract_t">Kaunitz AM, Kapoor E, Faubion S. Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause. JAMA 2021; 326:1429.</a></li><li><a class="nounderline abstract_t">“The 2022 Hormone Therapy Position  Statement of The North American Menopause Society” Advisory  Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022; 29:767.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA 2022; 328:1740.</a></li><li><a class="nounderline abstract_t">Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99:3543.</a></li><li><a class="nounderline abstract_t">Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310:1353.</a></li><li><a class="nounderline abstract_t">Manson JE, Aragaki AK, Bassuk SS, et al. Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. Ann Intern Med 2019; 171:406.</a></li><li><a class="nounderline abstract_t">Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17:55.</a></li><li class="breakAll">Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. ACOG Committee Opinion No. 774. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e279–84.</li><li><a class="nounderline abstract_t">Morelli M, Venturella R, Mocciaro R, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013; 129:448.</a></li><li class="breakAll">SGO Clinical Practice Statement: Salpingectomy for ovarian cancer prevention, November 2013. https://www.sgo.org/resources/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/#:~:text=SGO%20Clinical%20Practice%20Statement%3A%20Salpingectomy%20for%20Ovarian%20Cancer,site%20of%20origin%20may%20be%20the%20fallopian%20tube. (Accessed on July 07, 2020).</li><li><a class="nounderline abstract_t">Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 2011; 204:19.e1.</a></li><li class="breakAll">Salpingectomy recommended in British Columbia: http://www.ovcare.ca/prevention/ (Accessed on June 20, 2018).</li><li><a class="nounderline abstract_t">van Lieshout LAM, Steenbeek MP, De Hullu JA, et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev 2019; 8:CD012858.</a></li><li><a class="nounderline abstract_t">Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.</a></li><li><a class="nounderline abstract_t">Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 2015; 94:86.</a></li><li><a class="nounderline abstract_t">Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184.</a></li><li><a class="nounderline abstract_t">Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 2014; 102:192.</a></li><li><a class="nounderline abstract_t">Halmesmäki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004; 19:378.</a></li><li><a class="nounderline abstract_t">Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993; 168:765.</a></li><li><a class="nounderline abstract_t">Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG 2005; 112:956.</a></li></ol></div><div id="topicVersionRevision">Topic 14198 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576330" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Time Trends in Unilateral and Bilateral Oophorectomy in a Geographically Defined American Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733460" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216453" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661751" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Laparoscopic surgery for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36029832" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513637" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Progress in the management of tuboovarian abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8886700" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The residual ovary syndrome: a 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999301" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The feasibility and efficacy of laparoscopic oophorectomy in the management of pelvic pain after hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26741200" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Elective Oophorectomy: Primum Non Nocere.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576331" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Revised Markov Model Evaluating Oophorectomy at the Time of Hysterectomy for Benign Indication: Age 65 Years Revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055568" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ovarian conservation at the time of hysterectomy for benign disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384117" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635669" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518944" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34563499" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863124" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10658685" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35690930" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Menopause, hysterectomy, menopausal hormone therapy and cause-specific mortality: cohort study of UK Biobank participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37068275" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy : A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32585221" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774521" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of de novo cancer after premenopausal bilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193751" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of ovarian pathology after hysterectomy without oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635745" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk of oophorectomy after hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968347" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31482352" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of prior hysterectomy on surgical outcomes for laparoscopic adnexal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476145" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Surgical menopause and cardiovascular risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683211" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21178790" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574431" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cycle and hormone changes during perimenopause: the key role of ovarian function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159842" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519304" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ovarian androgen production in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966693" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20060093" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167486" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012044" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Survival patterns after oophorectomy in premenopausal women: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18714076" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prophylactic oophorectomy in premenopausal women and long-term health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prophylactic bilateral oophorectomy jeopardizes long-term health</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034050" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Increased cardiovascular mortality after early bilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24061049" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk of glaucoma after early bilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21336255" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955642" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329133" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bilateral Oophorectomy and Accelerated Aging: Cause or Effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101365" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30312584" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hysterectomy status and all-cause mortality in a 21-year Australian population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29162577" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826990" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fracture risk following bilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645540" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31738818" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186237" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hysterectomy and risk of cardiovascular disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27627190" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35862220" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risks of Stroke and Heart Disease Following Hysterectomy and Oophorectomy in Chinese Premenopausal Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29907243" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32563191" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25331207" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335682" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Age at natural menopause and risk of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221806" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Age at natural menopause and cause-specific mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684687" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women's Health Across the Nation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30232136" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CKD in Patients with Bilateral Oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35372385" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early Menopause May Associate With a Higher Risk of CKD and All-Cause Mortality in Postmenopausal Women: An Analysis of NHANES, 1999-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761551" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322406" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The long-term effects of oophorectomy on cognitive and motor aging are age dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202765" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761549" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Increased risk of parkinsonism in women who underwent oophorectomy before menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36287560" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35324541" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Contributions of oophorectomy and other gynecologic surgeries to cognitive decline and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34762113" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35102101" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Oophorectomy and rate of dementia: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724550" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476148" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Elective oophorectomy for benign gynecological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525904" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among women in midlife.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142982" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039407" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prophylactic oophorectomy at elective hysterectomy. Effects on psychological well-being at 1-year follow-up and its correlations to sexuality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18091177" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12733730" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fracture risk after bilateral oophorectomy in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500347" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580459" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hysterectomy and sexual functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098153" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Psychosexual health 5 years after hysterectomy: population-based comparison with endometrial ablation for dysfunctional uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267835" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Oophorectomy in premenopausal women: health-related quality of life and sexual functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490014" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hypoactive sexual desire disorder in menopausal women: a survey of Western European women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978095" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sexual problems and distress in United States women: prevalence and correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820815" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097975" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476149" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Surgical menopause: effects on psychological well-being and sexuality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22296433" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Assessment of sexuality after hysterectomy using the Female Sexual Function Index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488053" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hysterectomy controversies: ovarian and cervical preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486247" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Inappropriate oophorectomy at time of benign premenopausal hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20168105" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444994" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34636868" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35797481" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The 2022 hormone therapy position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318127" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25279572" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084921" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499528" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634209" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Tubal ligation and the risk of ovarian cancer: review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634209" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tubal ligation and the risk of ovarian cancer: review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558052" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558052" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619389" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619389" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456223" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476143" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25256594" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476141" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24825424" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747185" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456877" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957999" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The association of hysterectomy and menopause: a prospective cohort study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
